Solar Pharma Q3 revenue jumps 16% YoY as branded and revolutionary companies drive development
“Our revolutionary product providing has expanded additional with the launch of Unloxcyt within the US and the introduction of Ilumya in India. Collectively, these new initiatives convey differentiated therapies and significant innovation nearer to the sufferers,” stated Kirti Ganorkar, Managing Director, Solar Pharma.
The corporate’s Board has declared an interim dividend of Rs. 11.00 per share for FY26 in opposition to Rs 10.50 per share interim dividend for the earlier 12 months.
Formulation gross sales within the US had been $477 million, marginally up by 0.6%. The corporate’s revolutionary medicines enterprise continued to develop within the US, offsetting the decline in generics enterprise. US gross sales accounted for about 27.5% of complete consolidated gross sales. For the primary 9 months, gross sales had been $1,445 million.
Its international revolutionary medicines gross sales stood at $423 million for Q3FY26. This included a milestone revenue of $55 million. Ex-milestone, international revolutionary medicines gross sales had been up 13.2% and accounted for 21.2% of gross sales. For the primary 9 months, gross sales had been $1,067 million, up by 15.7% over the identical interval final 12 months.
Formulation gross sales in India had been Rs 49,98.60 crore, up 16.2%. India Formulation gross sales accounted for 32.3% of complete consolidated gross sales.
Solar’s revolutionary R&D pipeline consists of 5 novel entities within the medical stage. It has a complete product providing within the US market consisting of authorized ANDAs for 550 merchandise, whereas filings for 116 ANDAs await US FDA approval, together with 28 tentative approvals. Through the quarter, 2 ANDAs had been filed, and approval was acquired for two ANDAs. Solar’s portfolio consists of 57 authorized NDAs, whereas 14 NDAs await US FDA approval. Finish
